Shailendra Mani

Dr. Shailendra Mani

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2018 in Nature
Verified
Journal Article
Closed access
PDF file
PZPeng Zhou
Peng Zhou
HFHang Fan
Hang Fan
TLTian Lan
Tian Lan
XYxinglou yang
xinglou yang
WSWei-Feng Shi
Wei-Feng Shi
JMJingyun Ma
Jingyun Ma

25 February 2019 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
MAMatae Ahn
Matae Ahn
DADanielle Anderson
Danielle Anderson
QZQian Zhang
Qian Zhang
CTChee Wah Tan
Chee Wah Tan
BLBeng Lee Lim
Beng Lee Lim
LWLin-Fa Wang
Lin-Fa Wang

23 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SMShailendra Mani
Shailendra Mani
LTLav Tripathi
Lav Tripathi
RRRajendra Raut
Rajendra Raut
PTPoornima Tyagi
Poornima Tyagi
UAUpasana Arora
Upasana Arora
NKNavin Khanna
Navin Khanna
Dengue is a mosquito-borne viral disease with a global prevalence. It is caused by four closely-related dengue viruses (DENVs 1–4). A dengue vaccine that can protect against all four viruses is an unmet public health need. Live attenuated vaccine development efforts have encountered unexpected interactions between the vaccine viruses, raising safety concerns. This has emphasized the need to explore non-replicating dengue vaccine options. Virus-like particles (VLPs) which can elicit robust immunity in the absence of infection offer potential promise for the development of non-replicating dengue vaccine alternatives. We have used the methylotrophic yeast Pichia pastoris to develop DENV envelope (E) protein-based VLPs. We designed a synthetic codon-optimized gene, encoding the N-terminal 395 amino acid residues of the DENV-2 E protein. It also included 5’ pre-membrane-derived signal peptide-encoding sequences to ensure proper translational processing, and 3’ 6× His tag-encoding sequences to facilitate purification of the expressed protein. This gene was integrated into the genome of P. pastoris host and expressed under the alcohol oxidase 1 promoter by methanol induction. Recombinant DENV-2 protein, which was present in the insoluble membrane fraction, was extracted and purified using Ni2+-affinity chromatography under denaturing conditions. Amino terminal sequencing and detection of glycosylation indicated that DENV-2 E had undergone proper post-translational processing. Electron microscopy revealed the presence of discrete VLPs in the purified protein preparation after dialysis. The E protein present in these VLPs was recognized by two different conformation-sensitive monoclonal antibodies. Low doses of DENV-2 E VLPs formulated in alum were immunogenic in inbred and outbred mice eliciting virus neutralizing titers >1∶1200 in flow cytometry based assays and protected AG129 mice against lethal challenge (p<0.05). The formation of immunogenic DENV-2 E VLPs in the absence of pre-membrane protein highlights the potential of P. pastoris in developing non-replicating, safe, efficacious and affordable dengue vaccine.

1 September 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HPHilal Ahmad Parray
Hilal Ahmad Parray
ACAdarsh Kumar Chiranjivi
Adarsh Kumar Chiranjivi
SAShailendra Asthana
Shailendra Asthana
NYNaveen Yadav
Naveen Yadav
TSTripti Shrivastava
Tripti Shrivastava
RKRajesh Kumar
Rajesh Kumar
There is a desperate need for safe and effective vaccines, therapies and diagnostics for SARS-CoV-2, the development of which will be aided by the discovery of potent and selective antibodies against relevant viral epitopes. Human phage display technology has revolutionized the process of identifying and optimizing antibodies, providing facile entry points for further applications. Here in, we use this technology to search for antibodies targeting the receptor binding domain (RBD) of CoV-2. Specifically, we screened a naïve human semi-synthetic phage library against RBD, leading to the identification of a high-affinity single chain fragment variable region (scFv). The scFv was further engineered into two other antibody formats (scFv-Fc and IgG1). All the three antibody formats showed high binding specificity to CoV-2 RBD and the spike antigens in different assay systems. Flow cytometry analysis demonstrated specific binding of the IgG1 format to cells expressing membrane bound CoV-2 spike protein. Docking studies revealed that the scFv recognizes an epitope that partially overlaps with angiotensin converting enzyme 2 (ACE2)-interacting sites on the CoV-2 RBD. Given its high specificity and affinity, we anticipate that these anti-CoV-2 antibodies will be useful as valuable reagents for accessing the antigenicity of vaccine candidates, as well as developing antibody-based therapeutics and diagnostics for CoV-2.

23 September 2015 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
LTLav Tripathi
Lav Tripathi
SMShailendra Mani
Shailendra Mani
RRRajendra Raut
Rajendra Raut
APAnkur Poddar
Ankur Poddar
PTPoornima Tyagi
Poornima Tyagi
NKNavin Khanna
Navin Khanna
Dengue poses a serious public health risk to nearly half the global population. It causes ~400 million infections annually and is considered to be one of the fastest spreading vector-borne diseases. Four distinct serotypes of dengue viruses (DENV-1, -2, -3, and -4) cause dengue disease, which may be either mild or extremely severe. Antibody-dependent enhancement (ADE), by pre-existing cross-reactive antibodies, is considered to be the major mechanism underlying severe disease. This mandates that a preventive vaccine must confer simultaneous and durable immunity to each of the four prevalent DENV serotypes. Recently, we used Pichia pastoris, to express recombinant DENV-2 E ectodomain, and found that it assembled into virus-like particles (VLPs), in the absence of prM, implicated in the elicitation of ADE-mediating antibodies. These VLPs elicited predominantly type-specific neutralizing antibodies that conferred significant protection against lethal DENV-2 challenge, in a mouse model. The current work is an extension of this approach to develop prM-lacking DENV-3 E VLPs. Our data reveal that P. pastoris-produced DENV-3 E VLPs not only preserve the antigenic integrity of the major neutralizing epitopes, but also elicit potent DENV-3 virus-neutralizing antibodies. Further, these neutralizing antibodies appear to be exclusively directed toward domain III of the DENV-3 E VLPs. Significantly, they also lack discernible ADE potential toward heterotypic DENVs. Taken together with the high productivity of the P. pastoris expression system, this approach could potentially pave the way toward developing a DENV E-based, inexpensive, safe, and efficacious tetravalent sub-unit vaccine, for use in resource-poor dengue endemic countries.

13 September 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
ZRZAIGHAM ABBAS RIZVI
ZAIGHAM ABBAS RIZVI
JDJyotsna Dandotiya
Jyotsna Dandotiya
SSSrikanth Sadhu
Srikanth Sadhu
RKRitika Khatri
Ritika Khatri
JSJanmejay Singh
Janmejay Singh
AAAmit Awasthi
Amit Awasthi
A recently emerged sub-lineage of Omicron, BA.5, together with BA.4, caused a fifth wave of coronavirus disease (COVID-19) in South Africa and subsequently emerged as a predominant strain globally due to its high transmissibility. The lethality of BA.5 infection has not been studied in an acute hACE2 transgenic (hACE2.Tg) mouse model. Here, we investigated tissue-tropism and immuno-pathology induced by BA.5 infection in hACE2.Tg mice. Our data show that intranasal infection of BA.5 in hACE2.Tg mice resulted in attenuated pulmonary infection and pathology with diminished COVID-19-induced clinical and pathological manifestations. BA.5, similar to Omicron (B.1.1.529), infection led to attenuated production of inflammatory cytokines, anti-viral response and effector T cell response as compared to the ancestral strain of SARS-CoV-2, Wuhan-Hu-1. We show that mice recovered from B.1.1.529 infection showed robust protection against BA.5 infection associated with reduced lung viral load and pathology. Together, our data provide insights as to why BA.5 infection escapes previous SARS-CoV-2 exposure induced-T cell immunity but may result in milder immuno-pathology and alleviated chances of re-infectivity in Omicron-recovered individuals.